peptide research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
=== Regierung und Volksvertretung === Kennzeichen des Präsidenten der Abgeordnetenkammer (A-1), des Premierministers (A-2), der Mitglieder der Föderalregierung, der Staatsminister (ab A-26), der Vertreter der Hohen Magistratur (ab A-100), der Provinzgouverneure (ab A-130), der Vertreter des Hohen Klerus, der Generalsekretäre und Kabinettschefs der Föderalregierung bestehen aus einem A, einem mittigen Trennstrich und bis zu drei Ziffern. Kennzeichen des Präsidenten (P-1) und der Mitglieder des Senats, der Mitglieder der Abgeordnetenkammer, des Präsidenten und der Mitglieder des Flämischen oder Wallonischen Parlaments, des Präsidenten und der Mitglieder des Parlaments der Region Brüssel-Hauptstadt, des Präsidenten des Rates der Deutschsprachigen Gemeinschaft, der Mitglieder des Deutschsprachigen Parlamentes und der belgischen Mitglieder des Europäischen Parlamentes bestehen aus einem P, einem mittigen Trennstrich und bis zu drei Ziffern.
=== Mittlere Verwaltungsebene === Kennzeichen von Präsidenten, Mitgliedern oder Diensten der Gemeinschafts- und Regionalregierungen bestehen aus einem E, einem mittigen Trennstrich und bis zu drei Ziffern.
== Vorläufige Zulassungen == Ausländer oder Belgier, die sich nur vorübergehend in Belgien aufhalten und ein Kraftfahrzeug benutzen, das keine ausländischen Kennzeichen hat, bekommen ein vorläufiges Kennzeichen oder ein Transitkennzeichen, dessen Hintergrund rot (RAL 3020) ist. Die Schrift und der Rand sind weiß. Nach dem EU-Symbol folgen seit dem 2. Mai 2016 ein Buchstabenpaar, das mit einem W beginnt, ein Ziffernpaar, das das Jahr der Gültigkeit angibt, und drei Buchstaben. Motorräder erhalten die Buchstabenkombination WM, Anhänger die Kombination WQ sowie Mopeds und Kleinkraftwagen die Kombination WS. Die bisherigen Kennzeichen für vorläufige Zulassungen, die weiterhin gültig sind, enthielten die Ziffer 1, einen Strich und sechs weitere Ziffern. Am rechten Rand stand oben das Jahr und darunter der Monat, die das Ende der Gültigkeit des Kennzeichens angaben. Bei Kennzeichen für vorübergehende Kurzzeitzulassungen von Motorrädern sowie drei- oder vierrädrigen Krafträdern standen oben die Ziffer 1, ein kurzer Strich und drei Ziffern. In der unteren Reihe standen das EU-Symbol, die Gültigkeitsangabe und die letzten drei Ziffern. Die beiden Zifferngruppen standen genau übereinander. Die letzten ausgegebenen Kennzeichen tragen die Ziffernkombinationen 1-057002 und bei Motorrädern 1-999815
== Exportfahrzeuge == Personen, die ein Kraftfahrzeug ein- oder ausführen wollen, bekommen seit dem 2. Mai 2016 ein Exportkennzeichen, dessen Hintergrund rot (RAL 3020) ist. Die Schrift und der Rand sind weiß. Nach dem EU-Symbol folgen ein Buchstabenpaar, das mit einem X beginnt, ein Ziffernpaar, das das Jahr der Gültigkeit angibt, und drei Buchstaben. Motorräder erhalten die Buchstabenkombination XM, Anhänger die Kombination XQ sowie Mopeds und Kleinkraftwagen die Kombination XS.
Sources: de.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.